Lori Anne Kunkel Sells 10,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the sale, the director owned 51,884 shares of the company’s stock, valued at $1,792,073.36. This trade represents a 16.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN traded up $2.48 on Tuesday, reaching $36.11. 1,833,071 shares of the company traded hands, compared to its average volume of 1,121,074. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $48.53. The company’s 50 day moving average is $41.32 and its 200-day moving average is $30.28. The stock has a market capitalization of $2.20 billion, a PE ratio of -21.62 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after acquiring an additional 913 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares in the last quarter. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the first quarter worth $38,000. Finally, Swiss National Bank raised its holdings in shares of Enliven Therapeutics by 1.7% during the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after acquiring an additional 1,100 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ELVN shares. Mizuho increased their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. HC Wainwright increased their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Stifel Nicolaus started coverage on Enliven Therapeutics in a report on Tuesday. They issued a “buy” rating and a $60.00 target price for the company. Finally, Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $61.50.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.